These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892 [TBL] [Abstract][Full Text] [Related]
3. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin. Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757 [TBL] [Abstract][Full Text] [Related]
4. [The diagnosis and treatment of G3 neuroendocrine tumors according to the new NCCN guideline]. Liang Y; Yu XJ; Chen J Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):982-987. PubMed ID: 35399015 [TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208 [TBL] [Abstract][Full Text] [Related]
6. Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Holmager P; Langer SW; Kjaer A; Ringholm L; Garbyal RS; Pommergaard HC; Hansen CP; Federspiel B; Andreassen M; Knigge U Curr Treat Options Oncol; 2022 Jun; 23(6):806-817. PubMed ID: 35362798 [TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. Fazio N; Milione M Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009 [TBL] [Abstract][Full Text] [Related]
10. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors. Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616 [TBL] [Abstract][Full Text] [Related]
11. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Tang LH; Basturk O; Sue JJ; Klimstra DS Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms. Taboada R; Claro L; Felismino T; de Jesus VH; Barros M; Riechelmann RP J Neuroendocrinol; 2022 Apr; 34(4):e13099. PubMed ID: 35174558 [TBL] [Abstract][Full Text] [Related]
13. G3 GEP NENs category: are basic and clinical investigations well integrated? Milione M; Fazio N Endocrine; 2018 Apr; 60(1):28-30. PubMed ID: 28733935 [TBL] [Abstract][Full Text] [Related]
14. Expression and clinical value of CXCR4 in high grade gastroenteropancreatic neuroendocrine neoplasms. Pang C; Li Y; Shi M; Fan Z; Gao X; Meng Y; Liu S; Gao C; Su P; Wang X; Zhan H Front Endocrinol (Lausanne); 2024; 15():1281622. PubMed ID: 38524630 [TBL] [Abstract][Full Text] [Related]